Free Trial
→ The End of Elon Musk…? (From Brownstone Research) (Ad)
NASDAQ:XCUR

Exicure 8/11/2023 Earnings Report

Exicure logo
$8.76 -0.23 (-2.56%)
Closing price 06/13/2025 03:58 PM Eastern
Extended Trading
$8.76 0.00 (0.00%)
As of 06/13/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Exicure EPS Results

Actual EPS
-$3.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Exicure Announcement Details

Quarter
Date
8/11/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Exicure's next earnings date is estimated for Monday, June 16, 2025, based on past reporting schedules.

Conference Call Resources

Exicure Earnings Headlines

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
May 28, 2025 | businesswire.com
Why Exicure Inc. (XCUR) Soared on Monday
April 22, 2025 | msn.com
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
June 15, 2025 | Brownstone Research (Ad)
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
April 14, 2025 | businesswire.com
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...
April 11, 2025 | gurufocus.com
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
April 11, 2025 | investing.com
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR), an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

View Exicure Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles